title: Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta.
abstract: The use of previously successful antiretroviral regimens in mother-to-child transmission (MTCT) prevention will be increasingly challenged by the rising prevalence of multidrug-resistant (MDR) HIV. We used enfurvitide together with an optimized antiretroviral backbone to prevent the MTCT prevention of MDR HIV in two pregnant women. The measurement of maternal and foetal peripheral blood levels of enfurvitide showed no evidence of transplacental transfer.
authors.affiliation: Department of Genitourinary Medicine, St George's Hospital, London, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Brennan-Benson
authors.forename: Mark
authors.initials: M
authors.lastname: Pakianathan
authors.forename: Philip
authors.initials: P
authors.lastname: Rice
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonora
authors.forename: Rana
authors.initials: R
authors.lastname: Chakraborty
authors.forename: Michael
authors.initials: M
authors.lastname: Sharland
authors.forename: Phillip
authors.initials: P
authors.lastname: Hay
mesh_terms: D000328:Adult; D024921:Drug Resistance, Multiple, Viral; D000077560:Enfuvirtide; D005260:Female; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008431:Maternal-Fetal Exchange; D010446:Peptide Fragments / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*
chemical_list: D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide